The estimated Net Worth of Vincent O'neill is at least 512 千$ dollars as of 14 June 2024. Vincent neill owns over 521 units of BioXcel Therapeutics Inc stock worth over 2,023$ and over the last 9 years he sold BTAI stock worth over 0$. In addition, he makes 510,167$ as Chief Medical Officer at BioXcel Therapeutics Inc.
Vincent has made over 10 trades of the BioXcel Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 521 units of BTAI stock worth 287$ on 14 June 2024.
The largest trade he's ever made was exercising 29,713 units of BioXcel Therapeutics Inc stock on 20 January 2023 worth over 12,182$. On average, Vincent trades about 7,443 units every 84 days since 2016. As of 14 June 2024 he still owns at least 3,679 units of BioXcel Therapeutics Inc stock.
You can see the complete history of Vincent neill stock trades at the bottom of the page.
Dr. Vincent J. O'Neill M.D. serves as Chief Medical Officer of the Company. He served as the Chief Medical Officer of Mirna Therapeutics, Inc. from April 2016 to May 2017. From June 2014 to May 2016, he served as the Chief Medical Officer of Exosome Diagnostics, Inc., a diagnostics company. From 2012 to 2014, Dr. O'Neill was global head Personalized of Medicine and Companion Diagnostics at Sanofi S.A., a pharmaceutical company. From 2009 to 2012, Dr. O'Neill served as Group Director at Genentech, Inc. where he was involved in the expanded approval of products such as Avastin and Tarceva. From 2006 to 2009, Dr. O'Neill served as Director, Discovery Medicine at GlaxoSmithkline plc. Dr. O'Neill holds an M.D., MBChd and M.Sc. in Pathology from the University of Glasgow, UK.
As the Chief Medical Officer of BioXcel Therapeutics Inc, the total compensation of Vincent Neill at BioXcel Therapeutics Inc is 510,167$. There are 3 executives at BioXcel Therapeutics Inc getting paid more, with Vimal Mehta having the highest compensation of 1,968,930$.
Vincent Neill is 50, he's been the Chief Medical Officer of BioXcel Therapeutics Inc since 2017. There are 12 older and 2 younger executives at BioXcel Therapeutics Inc. The oldest executive at BioXcel Therapeutics Inc is Dr. Frank D. Yocca Ph.D., 65, who is the Sr. VP & Chief Scientific Officer.
Vincent's mailing address filed with the SEC is C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN, CT, 06511.
Over the last 7 years, insiders at BioXcel Therapeutics Inc have traded over 63,244,788$ worth of BioXcel Therapeutics Inc stock and bought 45,656 units worth 321,105$ . The most active insiders traders include Vimal Bio Xcel Holdings, In...、Vimal Mehta、Krishnan Nandabalan. On average, BioXcel Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of 29,814$. The most recent stock trade was executed by Matthew T. Wiley on 15 June 2024, trading 750 units of BTAI stock currently worth 413$.
bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
BioXcel Therapeutics Inc executives and other stock owners filed with the SEC include: